TY - JOUR

T1 - Incidence of malignancy in multiple sclerosis

T2 - A cohort study in the Danish Multiple Sclerosis Registry

AU - Nørgaard, Mette

AU - Veres, Katalin

AU - Sellebjerg, Finn T.

AU - Svingel, Lise S.

AU - Foch, Caroline

AU - Boutmy, Emmanuelle

AU - Sabidó, Meritxell

AU - Magyari, Melinda

N1 - Publisher Copyright: © The Author(s), 2021.

PY - 2021

Y1 - 2021

N2 - Background: The association between multiple sclerosis and malignancy is controversial and a current appraisal is needed. Objective: To determine the incidence of malignancy in patients with multiple sclerosis compared with the general population and in relation to disease-modifying therapy. Methods: Patients with multiple sclerosis (1995 – 2015) were matched by birth year and sex to individuals without multiple sclerosis in the general population. Patients with multiple sclerosis initiating disease-modifying therapy were evaluated using landmark period analysis. Malignancy risk was assessed by incidence rates, incidence rate ratios, and standardised incidence ratios. Results: The standardised incidence ratio of any malignancy (excluding non-melanoma skin cancer) in patients with multiple sclerosis (n = 10,557) was 0.96 (95% CI 0.88 – 1.06), and there was no increased incidence of specific malignancy types compared with the general population cohort (n = 103,761). At the 48-month landmark period, the age-adjusted incidence per 100,000 person-years of any malignancy (excluding non-melanoma skin cancer) was 436.7 (95% CI 361.0 – 512.4) in patients newly treated with immunomodulator-only and 675.1 (95% CI 130.4 – 1219.9) in patients newly treated with immunosuppressant-only. Conclusions: There was no increased incidence of malignancy overall or by type in patients with multiple sclerosis compared neither with the general population nor in relation to disease-modifying therapy.

AB - Background: The association between multiple sclerosis and malignancy is controversial and a current appraisal is needed. Objective: To determine the incidence of malignancy in patients with multiple sclerosis compared with the general population and in relation to disease-modifying therapy. Methods: Patients with multiple sclerosis (1995 – 2015) were matched by birth year and sex to individuals without multiple sclerosis in the general population. Patients with multiple sclerosis initiating disease-modifying therapy were evaluated using landmark period analysis. Malignancy risk was assessed by incidence rates, incidence rate ratios, and standardised incidence ratios. Results: The standardised incidence ratio of any malignancy (excluding non-melanoma skin cancer) in patients with multiple sclerosis (n = 10,557) was 0.96 (95% CI 0.88 – 1.06), and there was no increased incidence of specific malignancy types compared with the general population cohort (n = 103,761). At the 48-month landmark period, the age-adjusted incidence per 100,000 person-years of any malignancy (excluding non-melanoma skin cancer) was 436.7 (95% CI 361.0 – 512.4) in patients newly treated with immunomodulator-only and 675.1 (95% CI 130.4 – 1219.9) in patients newly treated with immunosuppressant-only. Conclusions: There was no increased incidence of malignancy overall or by type in patients with multiple sclerosis compared neither with the general population nor in relation to disease-modifying therapy.

KW - cohort

KW - Denmark

KW - disease-modifying therapy

KW - incidence

KW - malignancy

KW - Multiple sclerosis

KW - registry

U2 - 10.1177/20552173211053939

DO - 10.1177/20552173211053939

M3 - Journal article

C2 - 34840804

AN - SCOPUS:85120006083

VL - 7

JO - Multiple Sclerosis Journal - Experimental, Translational and Clinical

JF - Multiple Sclerosis Journal - Experimental, Translational and Clinical

SN - 2055-2173

IS - 4

ER -